The MRNA Therapeutics Contract Development & Manufacturing Market Size was valued at USD 3.12 billion in 2023 and is expected to reach USD 8.09 billion by 2032 and grow at a CAGR of 11.18% over the forecast period 2024-2032. This report points out the changing prescription and commercialization trends for mRNA-based therapies due to increasing demand for personalized medicine and novel vaccine development. The research delves into outsourcing trends, highlighting the growing dependence by pharma and biotech firms on contract development and manufacturing organizations (CDMOs) to drive efficiency in production and scalability. It further offers a cost and pricing analysis of mRNA production, determining the economic drivers impacting the efficiency of production and affordability. Trends in investment and funding are discussed, highlighting growing capital flows and strategic collaborations driving market growth. The report further explores the compliance and regulatory environment, reaching the pivotal nature of global policies in providing market access and assuring safety, as technological evolution in mRNA production continues to boost innovation and efficacy in the industry.
Market Dynamics
Drivers
The mRNA therapeutics contract development & manufacturing market is driven by the increasing demand for mRNA-based vaccines and therapeutics.
The success of COVID-19 vaccines, including those from Pfizer-BioNTech and Moderna, demonstrated the capabilities of mRNA technology, resulting in increased investment in mRNA research. The increasing pipeline of mRNA-based therapies for cancer, infectious diseases, and genetic disorders is further driving demand for dedicated CDMO services. Government support and collaborations between biotech companies and CDMOs are also driving market growth. For instance, in 2023, the U.S. government pledged USD 1.5 billion for investment in mRNA technology to enhance pandemic readiness. Furthermore, innovations in lipid nanoparticle (LNP) delivery systems have enhanced the stability and potency of mRNA medicines, enhancing their commercial appeal. CDMOs are also increasing their production capacity, with Lonza and Catalent investing heavily in new facilities to accommodate demand. Furthermore, the move toward personalized medicine and mRNA-based cancer immunotherapies is yielding long-term growth opportunities. Since pharmaceutical companies increasingly outsource the development and manufacture of mRNA, CDMOs are seeing revenues grow considerably, and the market is becoming increasingly competitive and dynamic.
Restraints
The market faces several key restraints, including high production costs and complex manufacturing processes.
mRNA therapeutics are manufactured in specialized facilities, using raw materials and expertise, hence the cost of manufacturing is high. The instability of mRNA also presents challenges that need ultra-cold storage at -70°C and special transportation logistics, thus raising the cost of the supply chain. Moreover, the scarcity of high-quality raw materials, e.g., nucleotides and lipid nanoparticles (LNPs), is a key bottleneck in bulk manufacturing. Regulatory issues also stifle market development, as mRNA treatments need to be subjected to rigorous quality control and approval from authorities such as the FDA and EMA, which results in delays in commercialization. Additionally, intellectual property (IP) restrictions can curtail innovation, with large players such as Moderna and BioNTech possessing key patents for mRNA technology. Small biotech companies tend to face challenges with funding and compliance with regulations, making it challenging for them to scale up manufacturing. Also, public uncertainty surrounding novel mRNA-based therapies outside of COVID-19 vaccines could hinder the adoption rate, especially in indications such as oncology and orphan diseases. All these factors cumulatively limit the widespread commercialization of mRNA therapeutics, which impacts the speed of market growth.
Opportunities
The growing adoption of mRNA technology beyond vaccines presents lucrative opportunities for the CDMO market.
mRNA cancer immunotherapies are becoming a key area of interest, with developers such as BioNTech and Moderna working on personalized cancer vaccines against individual tumor mutations. The increasing incidence of rare genetic disorders also presents opportunities for mRNA-based protein replacement therapy, driving demand for bespoke CDMO capabilities. In addition, public and private investments in mRNA R&D are driving innovation, with more than USD 5 billion in investments announced for future-generation mRNA technology in 2023. Another major opportunity is the development of self-amplifying mRNA (siRNA), which has lower doses and longer-duration effects. Growing manufacturing alliances in up-and-coming biotech hotspots and rising CDMO capacity expansions like Lonza's new mRNA plant are anticipated to keep pace with growing demand. The scope for oral and inhalable mRNA products is also gaining momentum, with easier delivery and wider applications. A further boost to market expansion could come from growing applications in cardiovascular and metabolic disorders. As pharmaceutical firms continue to outsource to CDMOs, companies that provide end-to-end solutions for mRNA development will be the ultimate beneficiaries, becoming players of choice for this growing market.
Challenges
The market faces significant challenges, particularly in scaling up mRNA manufacturing while maintaining quality and cost efficiency.
In contrast to traditional biologics, mRNA manufacturing is extremely precise, and even slight deviations in synthesis or purification can result in batch failure, raising the costs of operations. Supply chain disruption is still a significant challenge since the world is dependent on limited suppliers for raw materials such as capping enzymes, nucleotides, and LNPs, making procurement unpredictable. For instance, in 2023, lipid nanoparticle shortages caused production slowdowns in several CDMOs. Another significant challenge is intellectual property (IP) disputes since top companies like Moderna, Pfizer, and BioNTech are locked in disputes over mRNA-related patents, restricting entry for new players. Further, shortages of workers in advanced mRNA manufacturing processes cause bottlenecks with demand outstripping the availability of trained workers. Another challenge is regulatory complexity since approval procedures in regions vary and are cumbersome for mRNA-based therapeutics, complicating global commercialization. Lastly, long-term efficacy and safety issues are an issue, especially for mRNA therapies beyond infectious diseases. Overcoming these challenges will take strategic partnerships, supply chain diversification, and innovation in scalable manufacturing technologies to support sustainable market expansion.
By Application
The viral vaccines category dominated the mRNA therapeutics contract development & manufacturing market in 2023, with over 64.7% share of the overall revenue. Its dominance is the result of increased adoption of mRNA-based vaccines for COVID-19, influenza, and infectious diseases. Government subsidies, expedited regulatory clearances, and success in demonstrating mRNA vaccine efficacy further bolstered the market position of this category.
The protein replacement therapies segment is expected to be the most rapidly growing segment. The rising incidence of rare genetic and metabolic disorders, combined with advances in mRNA technology that allow for targeted protein expression, is driving demand for mRNA-based protein replacement therapies. Also, collaborations among biotech companies and CDMOs to create next-generation therapies are propelling swift market growth.
By Indication
The infectious diseases category led the market in 2023 with 61.3% of total revenue. This was driven mainly by the strong demand for mRNA-based vaccines against viral infections like COVID-19, RSV, and influenza. The efficacy, speed of development, and responsiveness of mRNA vaccines against new pathogen emergence have entrenched this segment as the market leader.
The segment of metabolic & genetic diseases is anticipated to experience the most rapid growth. The escalating incidence of rare genetic disorders, together with advancements in mRNA-based therapies for enzyme and protein replacement, is propelling segment growth. Furthermore, growing investments in gene editing technologies and precision medicine are also fuelling market growth.
By End-use
The biotech companies segment dominated the market in 2023 and accounted for more than 74.5% of the overall revenue. This leadership is due to the prominent position of biotech companies in establishing mRNA therapeutics, raising funds to support research, and offshoring manufacturing to CDMOs. Moreover, the nimbler nature of biotech companies in embracing new technologies has been a key driver of the mRNA CDMO market.
The government & academic research institutes segment is expected to be the fastest growing. Growing public sector investments in mRNA research, government-sponsored programs for creating pandemic preparedness plans, and academic institution partnerships with CDMOs are the primary drivers of high growth. The growth of government-funded R&D programs is also likely to increase contract development and manufacturing demand in this segment.
Regional Analysis
North America led the mRNA therapeutics contract development & manufacturing market in 2023, capturing more than 34.3% of the revenue. This is due to the dominance of major mRNA CDMOs, developed biopharmaceutical infrastructure, and heavy investment in the development of mRNA-based drugs. The U.S. specifically has witnessed increased demand for mRNA therapeutics and vaccines, backed by government initiative programs like Operation Warp Speed. Moreover, the availability of major biotech companies and pharmaceutical organizations outsourcing their production processes has further consolidated the market in this region.
Europe is another prominent market, fueled by rising government support, robust regulatory backing, and the availability of established biopharmaceutical clusters in Germany, the U.K., and France. The region has seen a boom in mRNA-based vaccine manufacturing, with CDMOs increasing their production capacity to address rising demand.
Asia-Pacific is likely to emerge as the fastest-growing regional market, driven by increasing investments in biopharmaceutical production, government efforts toward establishing domestic mRNA manufacturing capabilities, and the concentration of new-generation biotech companies. China, Japan, and South Korea are rapidly building CDMO capabilities to decrease their dependence on Western vendors.
Lonza
Samsung Biologics
BioNTech SE
Recipharm AB
TriLink BioTechnologies
Kaneka Eurogentec S.A.
Novo Holdings (Catalent, Inc.)
Danaher (Aldevron)
Biomay AG
Bio-Synthesis, Inc.
ethernet
ApexBio Technology
Biocina
Recent Developments
In Feb 2025, TriLink BioTechnologies, a Maravai LifeSciences company, entered a non-exclusive License and Supply Agreement with Aldevron, a global CDMO. This collaboration grants Aldevron customers access to TriLink’s CleanCap mRNA capping technology for non-commercial use, supporting the advancement of mRNA-based therapeutics and vaccines.
In Jan 2025, Meiji Seika Pharma received approval to add domestic manufacturing sites in Japan for KOSTAIVE, its self-amplifying mRNA COVID-19 vaccine. This amendment to its manufacturing and marketing approval aims to enhance local production capacity.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 3.12 billion |
| Market Size by 2032 | USD 8.09 billion |
| CAGR | CAGR of 11.18% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Application [Viral Vaccines, Protein Replacement Therapies, Cancer Immunotherapies] • By Indication [Infectious Diseases, Metabolic & Genetic Diseases, Cardiovascular & Cerebrovascular Diseases] • By End-use [Biotech Companies, Pharmaceutical companies, Government & Academic Research Institutes] |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Lonza, Samsung Biologics, BioNTech SE, Recipharm AB, TriLink BioTechnologies, Kaneka Eurogentec S.A., Novo Holdings (Catalent, Inc.), Danaher (Aldevron), Biomay AG, Bio-Synthesis, Inc., eTheRNA, ApexBio Technology, Biocina. |
Ans: The MRNA Therapeutics Contract Development & Manufacturing market is projected to grow at a CAGR of 11.18% during the forecast period.
Ans: By 2032, the MRNA Therapeutics Contract Development & Manufacturing market is expected to reach USD 8.09 billion, up from USD 3.12 billion in 2023.
Ans: The mRNA therapeutics contract development & manufacturing market is driven by the increasing demand for mRNA-based vaccines and therapeutics.
Ans: The market faces several key restraints, including high production costs and complex manufacturing processes.
Ans: North America is the dominant region in the MRNA Therapeutics Contract Development & Manufacturing market.
Table of content
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research & Academic Institutes Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research & Academic Institutes Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Prescription and Pharmaceutical Commercialization Trends for mRNA-Based Therapies (2023)
5.2 Outsourcing Trends: Pharma & Biotech Reliance on CDMOs (2023-2032)
5.3 Cost and Pricing Analysis of mRNA Manufacturing (2023-2032)
5.4 Investment and Funding Trends (2023-2032)
5.5 Regulatory and Compliance Landscape (2023-2032)
5.6 Technological Advancements in mRNA Manufacturing (2023-2032)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and Promotional Activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. MRNA Therapeutics Contract Development & Manufacturing Market Segmentation, by Application
7.1 Chapter Overview
7.2 Viral Vaccines
7.2.1 Viral Vaccines Market Trends Analysis (2020-2032)
7.2.2 Viral Vaccines Market Size Estimates and Forecasts to 2032 (USD Million)
7.3 Protein Replacement Therapies
7.3.1 Protein Replacement Therapies Market Trends Analysis (2020-2032)
7.3.2 Protein Replacement Therapies Market Size Estimates and Forecasts to 2032 (USD Million)
7.4 Cancer Immunotherapies
7.4.1 Cancer Immunotherapies Market Trends Analysis (2020-2032)
7.4.2 Cancer Immunotherapies Market Size Estimates and Forecasts to 2032 (USD Million)
8. MRNA Therapeutics Contract Development & Manufacturing Market Segmentation, by Indication
8.1 Chapter Overview
8.2 Infectious Diseases
8.2.1 Infectious Diseases Market Trends Analysis (2020-2032)
8.2.2 Infectious Diseases Market Size Estimates and Forecasts to 2032 (USD Million)
8.3 Metabolic & Genetic Diseases
8.3.1 Metabolic & Genetic Diseases Market Trends Analysis (2020-2032)
8.3.2 Metabolic & Genetic Diseases Market Size Estimates and Forecasts to 2032 (USD Million)
8.4 Cardiovascular & Cerebrovascular Diseases
8.4.1 Cardiovascular & Cerebrovascular Diseases Market Trends Analysis (2020-2032)
8.4.2 Cardiovascular & Cerebrovascular Diseases Market Size Estimates and Forecasts to 2032 (USD Million)
9. MRNA Therapeutics Contract Development & Manufacturing Market Segmentation, by End-use
9.1 Chapter Overview
9.2 Biotech Companies
9.2.1 Biotech Companies Market Trends Analysis (2020-2032)
9.2.2 Biotech Companies Market Size Estimates and Forecasts to 2032 (USD Million)
9.3 Pharmaceutical companies
9.3.1 Pharmaceutical Companies Market Trends Analysis (2020-2032)
9.3.2 Pharmaceutical Companies Market Size Estimates and Forecasts to 2032 (USD Million)
9.4 Government & Academic Research Institutes
9.4.1 Government & Academic Research Institutes Market Trends Analysis (2020-2032)
9.4.2 Government & Academic Research Institutes Market Size Estimates and Forecasts to 2032 (USD Million)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.2.3 North America MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.2.4 North America MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.2.5 North America MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.2.6 USA
10.2.6.1 USA MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.2.6.2 USA MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.2.6.3 USA MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.2.7 Canada
10.2.7.1 Canada MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.2.7.2 Canada MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.2.7.3 Canada MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.2.8 Mexico
10.2.8.1 Mexico MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.2.8.2 Mexico MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.2.8.3 Mexico MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.1.3 Eastern Europe MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.4 Eastern Europe MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.1.5 Eastern Europe MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.3.1.6 Poland
10.3.1.6.1 Poland MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.6.2 Poland MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.1.6.3 Poland MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.3.1.7 Romania
10.3.1.7.1 Romania MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.7.2 Romania MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.1.7.3 Romania MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.3.1.8 Hungary
10.3.1.8.1 Hungary MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.8.2 Hungary MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.1.8.3 Hungary MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.3.1.9 turkey
10.3.1.9.1 Turkey MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.9.2 Turkey MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.1.9.3 Turkey MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.10.2 Rest of Eastern Europe MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.1.10.3 Rest of Eastern Europe MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.2.3 Western Europe MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.4 Western Europe MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.2.5 Western Europe MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.3.2.6 Germany
10.3.2.6.1 Germany MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.6.2 Germany MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.2.6.3 Germany MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.3.2.7 France
10.3.2.7.1 France MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.7.2 France MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.2.7.3 France MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.3.2.8 UK
10.3.2.8.1 UK MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.8.2 UK MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.2.8.3 UK MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.3.2.9 Italy
10.3.2.9.1 Italy MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.9.2 Italy MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.2.9.3 Italy MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.3.2.10 Spain
10.3.2.10.1 Spain MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.10.2 Spain MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.2.10.3 Spain MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.11.2 Netherlands MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.2.11.3 Netherlands MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.12.2 Switzerland MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.2.12.3 Switzerland MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.3.2.13 Austria
10.3.2.13.1 Austria MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.13.2 Austria MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.2.13.3 Austria MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.14.2 Rest of Western Europe MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.3.2.14.3 Rest of Western Europe MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.4.3 Asia Pacific MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.4 Asia Pacific MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.4.5 Asia Pacific MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.4.6 China
10.4.6.1 China MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.6.2 China MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.4.6.3 China MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.4.7 India
10.4.7.1 India MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.7.2 India MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.4.7.3 India MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.4.8 Japan
10.4.8.1 Japan MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.8.2 Japan MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.4.8.3 Japan MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.4.9 South Korea
10.4.9.1 South Korea MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.9.2 South Korea MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.4.9.3 South Korea MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.4.10 Vietnam
10.4.10.1 Vietnam MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.10.2 Vietnam MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.4.10.3 Vietnam MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.4.11 Singapore
10.4.11.1 Singapore MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.11.2 Singapore MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.4.11.3 Singapore MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.4.12 Australia
10.4.12.1 Australia MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.12.2 Australia MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.4.12.3 Australia MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.13.2 Rest of Asia Pacific MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.4.13.3 Rest of Asia Pacific MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.1.3 Middle East MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.4 Middle East MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.5.1.5 Middle East MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.5.1.6 UAE
10.5.1.6.1 UAE MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.6.2 UAE MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.5.1.6.3 UAE MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.5.1.7 Egypt
10.5.1.7.1 Egypt MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.7.2 Egypt MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.5.1.7.3 Egypt MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.8.2 Saudi Arabia MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.5.1.8.3 Saudi Arabia MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.5.1.9 Qatar
10.5.1.9.1 Qatar MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.9.2 Qatar MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.5.1.9.3 Qatar MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.10.2 Rest of Middle East MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.5.1.10.3 Rest of Middle East MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.2.3 Africa MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.2.4 Africa MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.5.2.5 Africa MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.5.2.6 South Africa
10.5.2.6.1 South Africa MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.2.6.2 South Africa MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.5.2.6.3 South Africa MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.2.7.2 Nigeria MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.5.2.7.3 Nigeria MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.2.8.2 Rest of Africa MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.5.2.8.3 Rest of Africa MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.6.3 Latin America MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.6.4 Latin America MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.6.5 Latin America MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.6.6 Brazil
10.6.6.1 Brazil MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.6.6.2 Brazil MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.6.6.3 Brazil MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.6.7 Argentina
10.6.7.1 Argentina MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.6.7.2 Argentina MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.6.7.3 Argentina MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.6.8 Colombia
10.6.8.1 Colombia MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.6.8.2 Colombia MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.6.8.3 Colombia MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.6.9.2 Rest of Latin America MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.6.9.3 Rest of Latin America MRNA Therapeutics Contract Development & Manufacturing Market Estimates and Forecasts, by End-use (2020-2032) (USD Million)
11. Company Profiles
11.1 Lonza
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Product / Services Offered
11.1.4 SWOT Analysis
11.2 Samsung Biologics
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Product / Services Offered
11.2.4 SWOT Analysis
11.3 BioNTech SE
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Product / Services Offered
11.3.4 SWOT Analysis
11.4 Recipharm AB
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Product / Services Offered
11.4.4 SWOT Analysis
11.5 TriLink BioTechnologies
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Product / Services Offered
11.5.4 SWOT Analysis
11.6 Kaneka Eurogentec S.A.
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Product / Services Offered
11.6.4 SWOT Analysis
11.7 Novo Holdings (Catalent, Inc.)
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Product / Services Offered
11.7.4 SWOT Analysis
11.8 Danaher (Aldevron)
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Product / Services Offered
11.8.4 SWOT Analysis
11.9 Bio-Synthesis, Inc.
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Product / Services Offered
11.9.4 SWOT Analysis
11.10 ApexBio Technology
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Product / Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Application
Viral Vaccines
Protein Replacement Therapies
Cancer Immunotherapies
By Indication
Infectious Diseases
Metabolic & Genetic Diseases
Cardiovascular & Cerebrovascular Diseases
By End-use
Biotech Companies
Pharmaceutical companies
Government & Academic Research Institutes
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The Central Lab Market Size was USD 3.01 billion in 2023 and is expected to reach USD 4.98 billion by 2032, growing at a CAGR of 5.79% by 2024-2032.
The Exosome Diagnostics & Therapeutics Market was USD 36.0 million in 2023 and will reach USD 2962.8 Mn by 2032, growing at a CAGR of 63.25% by 2024-2032.
In Vivo CRO Market was valued at USD 4.7 billion in 2023 and is expected to reach USD 9.2 billion by 2032, growing at a CAGR of 8% over the forecast period 2024-2032.
Healthcare Payer Services Market was valued at USD 66.8 billion in 2023 and is expected to reach USD 125.58 billion by 2032, growing at a CAGR of 7.28% over the forecast period 2024-2032.
The Leptospirosis Market was valued at USD 501.0 million in 2023 and is expected to reach USD 868.2 million by 2032 with a growing CAGR of 6.3% from 2024 to 2032.
The Colorectal Cancer Therapeutics Market was valued at USD 12.7 billion in 2023 and is expected to reach USD 22.0 billion by 2032 and grow at a CAGR of 6.2% over the forecast period 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
